evo视讯官网

Be the most trusted biotech company

2026-03-12

Henlius Initiates a Phase 2/3 MRCT of Its Pan-Tumor PD-L1 ADC HLX43 for sqNSCLC in the US
2026-03-09

Henlius Announces IND Approval for Its Proprietary Next Generation Tetra-Specific T-Cell Engager HLX3901
2026-03-09

IND Application for Potential First‑in‑Class B7‑H3–Targeting Sialidase Fusion Protein HLX316 Approved in China
2026-03-06

Results of Serplulimab in Lung Cancer Selected for ELCC 2026，continuously demonstrating its efficacy and potential
2026-03-05

Henlius Receives IND Approval for Its Potential BIC Novel Oral KAT6A/B Small Molecule Inhibitor HLX97
2026-03-02

One-Year Anniversary of EU Approval: Hetronifly® Now Launched in 12 EU Countries and Reimbursed in 7
2026-02-28

Henlius Obtains Japan MAH License Strengthening Presence in the World’s Fourth-Largest Pharmaceutical Market
2026-02-28

Henlius Doses First Patient in Phase 2/3 Trial of HLX22 for First-Line Treatment of HER2-Positive Breast Cancer
2026-02-27

EMA CHMP Recommends EU Approval of Henlius’ Pertuzumab Biosimilar HLX11

1
...
4
5
6
7
8
9
...
60